vs. Single-Entity Products: Products may be packaged together but not physically combined, or fully integrated as a single product.

These definitions form the foundation for regulatory classification and submission planning worldwide.

Global Regulatory Frameworks for Combination Products

Combination products fall under distinct but overlapping frameworks:

• FDA (US): Governed under 21 CFR Part 3 with lead centers (CDER, CBER, or CDRH) determined by PMOA. Submissions can be NDA, BLA, or PMA/510(k) with additional requirements.
• EMA (EU): Combination products regulated under EU MDR (2017/745) when a device incorporates a medicinal substance. Marketing Authorisation Applications (MAA) must demonstrate safety and performance.
• CDSCO (India): Combination drugs governed by Schedule Y and MDR 2017, with review committees assessing both drug and device aspects.
• ROW Markets: Countries like Japan (PMDA) and Brazil (ANVISA) have hybrid frameworks aligned with US/EU systems.

RA professionals must design strategies that integrate both drug and device regulations while addressing region-specific requirements.

Processes and Workflow for Combination Product Approvals

A typical workflow for combination product approvals includes:

1. Classification: Determine PMOA and regulatory jurisdiction.
2. Pre-Submission Consultation: Engage early with FDA OCP, EMA scientific advice, or CDSCO expert committees.
3. Dossier Preparation: Compile CTD/eCTD modules (for drug/biologic) and technical device documentation.
4. Clinical/Nonclinical Studies: Generate integrated safety and performance data covering both components.
5. Regulatory Submission: Submit NDA/BLA + device dossier (FDA), MAA with Annex I MDR compliance (EMA), or Form CTD/SUGAM portal (CDSCO).
6. Regulatory Review: Address queries across drug and device divisions, ensuring consistency.
7. Approval & Launch: Market authorization granted with conditions for pharmacovigilance and post-market device surveillance.
8. Post-Approval Monitoring: Maintain ongoing safety updates, vigilance reporting, and lifecycle compliance.

This workflow highlights the multidisciplinary nature of combination product approvals.

Case Study 1: FDA Drug-Device Combination

Case: In 2022, FDA reviewed a prefilled autoinjector containing a biologic therapy.

• Challenge: Balancing drug stability with device functionality.
• Action: Company submitted an NDA with device master file cross-references and usability studies.
• Outcome: FDA approved the product with post-market human factors surveillance requirements.
• Lesson Learned: Human factors and usability are critical for FDA combination product approvals.

Case Study 2: EMA MDR Combination

Case: A European company submitted an inhaler-drug combination under EU MDR in 2023.

• Challenge: EMA required robust demonstration of device performance and medicinal benefit.
• Action: Submitted MAA with Annex I MDR documentation and performance testing results.
• Outcome: EMA approved the product, contingent on periodic device re-certification.
• Lesson Learned: EU MDR compliance is equally critical as medicinal safety for EU approvals.

Tools, Templates, and Systems Used

Combination product approvals require specialized resources:

• FDA Guidance: Combination Product Quality Considerations, Human Factors Studies.
• EMA MDR Annex I Templates: Standardized checklists for drug-device combinations.
• RIM Systems: Platforms to track integrated submissions across drug and device components.
• Clinical Protocol Templates: Designed for hybrid studies covering pharmacology and device usability.
• Inspection Readiness Tools: Checklists for both GMP and ISO 13485 compliance.

These tools help ensure compliance and harmonization of submissions.

Common Challenges and Best Practices

Combination product submissions face significant hurdles:

• Jurisdictional Complexity: Overlapping drug and device regulations create uncertainty.
• Data Integration: Harmonizing clinical and device performance evidence in one dossier.
• Lifecycle Management: Managing post-approval variations and re-certifications.
• Inspection Risks: Companies may face both drug GMP and device ISO 13485 audits.

Best practices include early engagement with regulators, maintaining parallel drug-device documentation, implementing integrated quality systems, and ensuring clear communication across cross-functional teams.

Latest Updates and Strategic Insights

As of 2025, trends in combination product regulation include:

• eCTD 4.0 Integration: Expansion to accommodate device-related modules in combination submissions.
• Human Factors Emphasis: Regulators demanding robust usability data, especially for self-administered devices.
• Global Harmonization: ICH and IMDRF working toward unified guidelines for drug-device products.
• Digital Health Integration: Expansion of digital components (apps, sensors) in combination products requiring regulatory adaptation.
• Lifecycle Alignment: Post-market obligations increasingly tied to both pharmacovigilance and device vigilance systems.

Strategically, RA professionals must prepare for hybrid regulatory pathways that integrate drug, device, biologic, and digital components under a single compliance umbrella.

Conclusion

Combination product approvals represent the intersection of pharmaceutical and device regulations, demanding multidisciplinary expertise. By mastering global frameworks, designing integrated dossiers, leveraging regulatory templates, and aligning lifecycle management, RA professionals can achieve compliance and market access. In 2025 and beyond, combination product regulation will continue to evolve with digital health, biologics, and advanced therapies, shaping the future of global healthcare.